Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Umeclidinium in Primary Palmar Hyperhidrosis
NCT02673619Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in primary palmar hyperhidrosis (PPH) comparing Umeclidinium 1.85% with Vehicle (2 arms). Primary endpoints: Posterior Probability That the Response Rate is Greater Than 50% at Day 29 and Percentage of Participants With at Least 30 Percent Reduction From Baseline in Sweat Production at Day 29. Started Mar 2016; status: completed.
02
Drugs
umeclidinium
03
Conditions
primary palmar hyperhidrosis (PPH)
Beyond the preview
Go deeper on NCT02673619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673619.